Topics

Efforts Continue to Perfect PARPi Use in Ovarian Cancer

16:10 EST 7 Nov 2019 | OncLive

As PARP inhibitors have now moved into the frontline maintenance setting in ovarian cancer, researchers are now seeking to even further capitalize on use of these agents, including indications in treatment-naïve patients.

Original Article: Efforts Continue to Perfect PARPi Use in Ovarian Cancer

NEXT ARTICLE

More From BioPortfolio on "Efforts Continue to Perfect PARPi Use in Ovarian Cancer"

Quick Search

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...